Navigation Links
Luminex MAGPIX System Shown to be More Cost Effective and Efficient Than Conventional ELISA Method in Initial Study
Date:9/8/2010

AUSTIN, Texas, Sept. 8 /PRNewswire-FirstCall/ -- Luminex Corporation (Nasdaq: LMNX), today announced that initial results from a study conducted at the NMI Natural and Medical Sciences Institute at the University of Tubingen in Germany demonstrate that its MAGPIX® system provides more cost effective and efficient results than a conventional microtiter plate based ELISA method.

(Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20100104/LUMINEXLOGO)

"These initial results demonstrate why MAGPIX could be a good choice for every research laboratory," said Dr. Thomas Joos, the head of the Biochemistry Department at the Natural and Medical Sciences Institute. "The system is a great choice for labs seeking one platform that allows the efficiency of multiplexing as well as the ability to run single tests, as needed. It can help labs save resources, increase efficiency and maximize results."

The NMI Natural and Medical Sciences Institute performed a comparative study between the recently launched MAGPIX system and a conventional ELISA method.  The study utilized an assay for soluble tumor necrosis factor receptor II to compare the analytical methods using several parameters including optimal detection antibody concentration, dynamic range and assay sensitivity, sample measurement, intra- and inter-assay precision, parallelism, and dilution linearity.  In addition to analytical performance, a time and motion analysis, and a cost comparison was performed.

The findings from this initial study demonstrate that MAGPIX provides accurate assay results at costs of as much as half of the microtiter plate ELISA method with equivalent sensitivity. While total assay and hands-on time for MAGPIX and ELISA were similar, MAGPIX is capable of producing up to 50 results in the same amount of time as one ELISA sample while requiring the same amount of sample material.

"We are very pleased with the findings of Dr. Joos's study at NMI, demonstrating strong performance of MAGPIX in relation to conventional ELISA testing," said Patrick J. Balthrop, president and CEO of Luminex.  "These initial data highlight the importance of MAGPIX as a scientific tool for any lab seeking to enhance productivity and bring the power of multiplexing to their day-to-day research."

Luminex's MAGPIX system is a compact analytical instrument capable of performing up to 50 tests on a single sample providing nearly 5,000 data points in under an hour. The easy-to-use and simple-to-deploy instrument was designed to meet the needs of scientists and researchers who have not been able to take advantage of the power of multiplexing because of resource or space limitations.

Based on Luminex's xMAP® Technology, MAGPIX provides fast, accurate and easily reproducible results and saves laboratory time and resources.  Like all of Luminex's instruments, it is versatile and flexible and can be used to analyze both nucleic acids and proteins, making it applicable in many research settings.

For more information on MAGPIX, call 512.219.8020, or visit www.luminexcorp.com/magpix.

About Luminex CorporationLuminex Corporation develops, manufactures and markets proprietary biological testing technologies with applications throughout the diagnostic and life sciences industries. The Company's xMAP® multiplex solutions include an open-architecture, multi-analyte technology platform that delivers fast, accurate and cost-effective bioassay results to markets as diverse as pharmaceutical drug discovery, clinical diagnostics and biomedical research, including the genomics and proteomics markets. The Company's xMAP Technology is sold worldwide and is already in use in leading clinical laboratories as well as major pharmaceutical, diagnostic and biotechnology companies. Further information on Luminex Corporation or xMAP Technology can be obtained at www.luminexcorp.com.Luminex Contacts:Harriss T. Currie, 512-219-8020Vice President, Finance and Chief Financial Officerhcurrie@luminexcorp.comMimi L. Torrington, 512-219-8020Director of Investor Relationsmtorrington@luminexcorp.comMedia:Nicole L. Cottrill, 615-327-7999ncottrill@seigenthaler.com
'/>"/>

SOURCE Luminex Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Luminex Donates Companys First MAGPIX Multiplexing System to Papua New Guinea Institute of Medical Research
2. Luminex Announces Commercial Launch of New Cystic Fibrosis Test
3. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
4. CardioFocus Endoscopic Ablation System Earns CE Mark to Treat Atrial Fibrillation; US Clinical Investigation Underway
5. Siemens Preclinical Imaging System Helps The Methodist Hospital in Houston Further Its Research Mission
6. Syndicom SpineConnect Web Platform Chosen for Applied Spines Leg and Back Pain Clinical Trial of Its Stabilimax NZ(R) Dynamic Spine Stabilization System
7. Life Recovery Systems Receives European CE Mark Approval for Its ThermoSuit(R) System
8. New Topical Therapy Safely Treats Serious Skin Infections Without Systemic Side Effects
9. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
10. Abbott Initiates Clinical Study to Evaluate Use of RX Herculink(R) Elite(TM) Renal Stent System for the Treatment of Renal Artery Stenosis
11. Neupro(R) (Rotigotine Transdermal System) Effective in Controlling Early Morning Motor Impairment and Generally Well-Tolerated for Long-Term Use in Patients with Parkinsons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/28/2017)... 28, 2017 Hill-Rom Holdings, Inc. (NYSE: HRC), ... call and webcast on Friday, November 3, 2017, beginning ... ending at approximately 8:30 a.m. (CDT) / 9:30 a.m. ... 2017 financial performance and guidance for 2018, Hill-Rom executives ... enhance operational performance, and long-range financial outlook through 2020. ...
(Date:9/25/2017)... --  Montrium , an industry leader in powerful ... Trial Master Files & Inspection Readiness Conference ( ... Services has selected eTMF Connect to ... a leading European contract research organization (CRO), will ... enable greater collaboration with sponsors, improve compliance and ...
(Date:9/22/2017)... , Sept. 22, 2017 AVACEN Medical ... device is now successfully helping those with the widespread ... Fibromyalgia diagnosed Amanda in Essex, England ... and washing my hair, experiencing no sleep at all, ... painful spasm… I cannot recommend [the AVACEN 100] enough, ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed a ... and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been ... standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... The American ... Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium ... 8. , In honor of Morris F. Collen, a pioneer in the field of ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... drug delivery system that we intend to develop to enable prevention of a ... lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss ...
(Date:10/12/2017)... PA (PRWEB) , ... October 12, 2017 , ... ... is the recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B ... York City on October 11, 2017. , The annual award competition recognizes editorial and ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, the Health & Wellness ... Moonlight to raise money for the American Heart Association Heart Walk. Teams of up ... work together to keep their treadmills moving for 5 hours. Treadmills will start at ...
Breaking Medicine News(10 mins):